Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon-gamma + anidulafungin
- Development stage
- Unknown
- Lead developer
- Radboud University Medical Center
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
interferon-gamma + anidulafungin is a combination therapy investigated for the treatment of candidemia, a systemic fungal infection. This regimen combines the immunomodulatory effects of recombinant interferon-gamma (IFN-γ) with the direct antifungal activity of anidulafungin. IFN-γ is a cytokine that enhances the host's innate and adaptive immune responses, specifically by activating macrophages and increasing the production of reactive oxygen species to facilitate fungal clearance. Anidulafungin is an echinocandin antifungal that inhibits 1,3-beta-D-glucan synthase, an enzyme essential for synthesizing the fungal cell wall component 1,3-beta-D-glucan. By combining these two agents, the therapy aims to both weaken the pathogen and bolster the patient's immune defenses. This combination was notably evaluated in a Phase 2 pilot study (NCT01444820) led by Radboud University Medical Center.
- Brand names
- ActimmuneEraxisImukin
- Other names
- IFN-gamma + anidulafunginrecombinant interferon-gamma + anidulafungin
02
Targets
IFNGR1 (Interferon gamma receptor 1)FKS (1,3-beta-D-glucan synthase component FKS1)
Beyond the preview
Go deeper on interferon-gamma + anidulafungin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon-gamma + anidulafungin.